

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10756153
Filing Date	2004-01-13
First Named Inventor	Leslie Johnson
Art Unit	1644
Examiner Name	Crowder, Chun
Attorney Docket Number	13783-10515

U.S. PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10756153
Filing Date	2004-01-13
First Named Inventor	Leslie Johnson
Art Unit	1644
Examiner Name	Crowder, Chun
Attorney Docket Number	13783-10515

/MS/	C1	TAMM A ET AL: "The binding epitopes of human CD16 (FcγRIII) monoclonal antibodies" JOURNAL OF IMMUNOLOGY, vol. 157, 1996, pages 1576-1581	<input type="checkbox"/>
	C2	SOUBRANE C ET AL: "BIOLOGIC RESPONSE TO ANTI-CD16 MONOCLONAL ANTIBODY THERAPY IN A HUMAN IMMUNODEFICIENCY VIRUS-RELATED IMMUNE THROMBOCYTOPENIC PURPURA PATIENT" BLOOD, vol. 81, no. 1, January 1993 (1993-01), pages 15-19	<input type="checkbox"/>
	C3	MANDELBOIM OFER ET AL: "Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, vol. 96, no. 10, 11 May 1999 (1999-05-11), pages 5640-5644	<input type="checkbox"/>
	C4	RADAEV S ET AL: "The Structure of a Human Type III Fc[γ] Receptor In Complex with Fc" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, vol. 276, no. 19, 31 January 2001 (2001-01-31), pages 16469-16477	<input type="checkbox"/>
↓ /MS/	C5	EP Search Report Dated 9/25/07	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Michael Szperka/	Date Considered	11/13/2008
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.